Cancer Research UK and its partners have today (Friday) launched a clinical trial to test if a drug that’s used to treat inflammation of the pancreas can help people with COVID-19.
29 May, 2020
EIT Health launches an in-depth framework for adopting and accelerating Value-Based Health Care (VBHC) across Europe. The framework advises how healthcare services can improve patient outcomes and reduce wasted resources. It is published within a new handbook that draws on the experiences of over 240 European VBHC pioneers across 22 countries in Europe, including 32 site visits in leading medical centres.
29 May, 2020
Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that the Company has recently won several new contracts to support pharmaceutical clients in delivering virtual clinical trials, including two contracts collectively worth over £1 million - the majority of which is expected to be recognised this financial year.
28 May, 2020
CHOSOURCE platform to be combined with Rentschler Biopharma’s novel in-house cell line development process to provide speed, stability and high yield
22 May, 2020
Glasgow, Scotland, 21 May 2020 - Amphista Therapeutics, a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes to remove disease causing proteins selectively and efficiently, today announced the appointment of Dr Ian Churcher as Chief Scientific Officer (CSO).
21 May, 2020
A ‘virtual VMIC’ will be created to rapidly expand the UK capacity to manufacture a COVID-19 vaccine. VMIC’s permanent facility, currently being built, will be fast tracked to come online in Summer 2021 – a year ahead of schedule. Manufacturing output at the permanent facility will be scaled-up 20fold to ensure enough doses of a pandemic vaccine for the UK population within 4-6 months of opening.
18 May, 2020
Stockholm, May 1st, 2020 – Swedish biotechnology company CARTANA today announced the launch of a new range of In Situ Sequencing (ISS) reagent kits designed to increase the efficiency and enable ISS on virtually any tissue sample. Users will be able to analyse either fresh/fixed frozen or FFPE samples and rapidly create single cell gene expression maps of up to 600 genes.
14 May, 2020
Cambridge and Wetherby, UK, 11 May 2020: Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that today it is shipping Affimer reagents for COVID-19 antigen testing to its diagnostic test development partners.
13 May, 2020
Fingerprint testing provides results in 10 minutes, with no need for medical staff.Portable and non-invasive, fingerprint-based method is ideal for on-site testing in care homes and the workplace
13 May, 2020
Oxford BioDynamics’ EpiSwitch technology has been chosen as the biomarker platform for prognostic and predictive profiling of COVID-19 patients in the GETAFIX clinical study.Institute of Infection, Immunity and Inflammation, University of Glasgow, and NHS Scotland are leading the effort to identify patients at risk of severe immune complications and those patients who can benefit from treatment with the anti-viral favipiravir.The EpiSwitch platform has already delivered prognostic and predictive biomarker developments and validations in collaboration with University of Glasgow Professors Iain McInnes and Carl Goodyear, as well as with EMD Serono, Pfizer, Genentech, Roche, Mayo Clinic and Massachusetts General Hospital.
01 May, 2020